ATE506957T1 - Prophylaktisches/therapeutisches mittel für neurodegenerative erkrankungen - Google Patents

Prophylaktisches/therapeutisches mittel für neurodegenerative erkrankungen

Info

Publication number
ATE506957T1
ATE506957T1 AT07742308T AT07742308T ATE506957T1 AT E506957 T1 ATE506957 T1 AT E506957T1 AT 07742308 T AT07742308 T AT 07742308T AT 07742308 T AT07742308 T AT 07742308T AT E506957 T1 ATE506957 T1 AT E506957T1
Authority
AT
Austria
Prior art keywords
protein
prophylactic
therapeutic agent
neurodegenerative diseases
acid sequence
Prior art date
Application number
AT07742308T
Other languages
English (en)
Inventor
Hitoshi Okazawa
Original Assignee
Nat Univ Corp Tokyo Med & Dent
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nat Univ Corp Tokyo Med & Dent filed Critical Nat Univ Corp Tokyo Med & Dent
Application granted granted Critical
Publication of ATE506957T1 publication Critical patent/ATE506957T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT07742308T 2006-06-01 2007-04-24 Prophylaktisches/therapeutisches mittel für neurodegenerative erkrankungen ATE506957T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2006154059A JP4982739B2 (ja) 2006-06-01 2006-06-01 ポリグルタミン病の予防・治療剤
PCT/JP2007/058873 WO2007138810A1 (ja) 2006-06-01 2007-04-24 神経変性疾患の予防・治療剤

Publications (1)

Publication Number Publication Date
ATE506957T1 true ATE506957T1 (de) 2011-05-15

Family

ID=38778331

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07742308T ATE506957T1 (de) 2006-06-01 2007-04-24 Prophylaktisches/therapeutisches mittel für neurodegenerative erkrankungen

Country Status (6)

Country Link
US (1) US7833975B2 (de)
EP (1) EP2039367B1 (de)
JP (1) JP4982739B2 (de)
AT (1) ATE506957T1 (de)
DE (1) DE602007014210D1 (de)
WO (1) WO2007138810A1 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5676253B2 (ja) 2008-04-30 2015-02-25 株式会社ジェノミックス 生体内機能的細胞の高効率採取法
JP5865703B2 (ja) 2009-10-28 2016-02-17 株式会社ジェノミックス 骨髄間葉系および/または多能性幹細胞の血中動員による組織再生促進剤
PT3358011T (pt) 2011-04-26 2020-04-23 Univ Osaka Péptido para induzir a regeneração de um tecido e a sua utilização
ES2660420T3 (es) 2012-10-25 2018-03-22 Genomix Co., Ltd. Método novedoso para tratar infarto cardiaco utilizando fragmento de HMGB1
US9688733B2 (en) * 2012-10-25 2017-06-27 Genomix Co., Ltd. Method for treating spinal cord injury using HMGB1 fragment
US10989719B2 (en) 2013-10-11 2021-04-27 National University Corporation Tokyo Medical And Dental University Methods for treating spinocerebellar ataxia type I using RPA1
WO2018030405A1 (ja) * 2016-08-09 2018-02-15 国立大学法人東京医科歯科大学 Hmgb1に対する抗体、及びそれを含有するアルツハイマー病を治療又は予防するための組成物
JP6984815B2 (ja) * 2016-09-12 2021-12-22 国立大学法人 東京医科歯科大学 神経変性疾患タンパク質の異常凝集を伴って発症する神経疾患に対する予防又は治療剤、及び上記予防又は治療剤のスクリーニング方法
EP3556378B1 (de) 2017-01-27 2025-03-12 StemRIM Inc. Therapeutisches mittel für kardiomyopathie, alten myokardinfarkt und chronisches herzversagen
CN111868231B (zh) 2017-12-01 2024-05-31 斯特姆里姆有限公司 外胚层间充质干细胞及其产生方法
CN111542335A (zh) 2017-12-01 2020-08-14 斯特姆里姆有限公司 炎症性肠病的治疗药
US20210024594A1 (en) 2018-02-08 2021-01-28 StemRIM Inc. Therapeutic Agent for Psoriasis
US12304933B2 (en) 2018-10-05 2025-05-20 StemRIM Inc. Disease treatment drug based on mesenchymal-stem-cell mobilization
US20250019405A1 (en) * 2020-04-22 2025-01-16 Chulalongkorn University A Composition and A Method of Rejuvenating DNA and Preventing DNA Damage

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4255101B2 (ja) 2002-03-15 2009-04-15 独立行政法人理化学研究所 神経変性疾患の治療薬
WO2004061456A2 (de) * 2003-01-03 2004-07-22 Alcedo Biotech Gmbh Verwendungen von hmgb, hmgn, hmga proteinen
WO2005025604A2 (en) * 2003-09-10 2005-03-24 The General Hospital Corporation Use of hmgb and hmgb fragments to decrease specific immune response
AU2004272607B2 (en) * 2003-09-11 2008-11-06 Cornerstone Therapeutics Inc. Monoclonal antibodies against HMGB1
US7618793B2 (en) * 2004-10-20 2009-11-17 The Regents Of The University Of Washington Identifying agents for decreasing cellular toxicity associated with huntingin polypeptide

Also Published As

Publication number Publication date
US7833975B2 (en) 2010-11-16
EP2039367A4 (de) 2009-12-30
US20090280488A1 (en) 2009-11-12
DE602007014210D1 (de) 2011-06-09
JP4982739B2 (ja) 2012-07-25
EP2039367A1 (de) 2009-03-25
WO2007138810A1 (ja) 2007-12-06
EP2039367B1 (de) 2011-04-27
JP2007320919A (ja) 2007-12-13

Similar Documents

Publication Publication Date Title
ATE506957T1 (de) Prophylaktisches/therapeutisches mittel für neurodegenerative erkrankungen
ATE483027T1 (de) Rekombinante n-glykosylierte proteine aus prokaryontischen zellen
EA201170878A1 (ru) Полипептиды с ксиланазной активностью
WO2004078777A3 (en) Dipeptidyl-peptidase protected proteins
SE0301010D0 (sv) Novel compounds
WO2009004315A8 (en) Isolated peptides and uses thereof
MX2008001865A (es) Proteinas de fusion de albumina.
SE0301009D0 (sv) Novel compounds
IN2012DN03368A (de)
EP2455460A3 (de) Lipasevarianten zur pharmazeutischen Verwendung
SG170116A1 (en) Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
GB2431404A (en) Peptide
WO2008074840A3 (en) Amino acid sequences directed against a metalloproteinase from the adam family and polypeptides comprising the same for the treatment of adam-related diseases and disorders
ATE417595T1 (de) Keratin-bindende polypeptide
MX2009006617A (es) Composiciones que contienen, metodos que involucran y usos de aminoacidos y polipeptidos no naturales.
NO20054769L (no) Substituerte fenylalkansyrer
WO2011036443A9 (en) S1 protease c- terminal polypeptides and uses thereof for treating inflammation or coagulation disorders
WO2008061208A3 (en) Arylsulfonamide compounds
MX2008009493A (es) Peptido novedoso y uso del mismo.
EP1801206A4 (de) Verfahren zur herstellung von l-arginin, l-ornithin oder l-citrullin
WO2009024327A3 (en) New proteins for use in human and animal staphylococcus infections
WO2008051326A3 (en) Identification of contactins and l1- cams as ligands for the amyloid precursor protein
WO2005059131A3 (en) Protein binding miniature proteins and uses thereof
WO2010103515A3 (en) Compositions and methods for prevention and treatment of neurodegenerative diseases
WO2007132292A3 (en) Therapy for alzheimer's disease

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties